SCHEMBL13289293

SCHEMBL13289293

Bc1cnn2c(NC3CCN(S(=O)(=O)CC)CC3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.46
CCNT1 O60563 1/20 0.43
CDK2 P24941 4/20 0.42
HSD11B1 P28845 1/20 0.40
CCND1 P24385 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK6 Q00534 1/20 0.39
MAPK14 Q16539 1/20 0.38
MEN1 O00255 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
KMT2A Q03164 2/20 0.37
NR2F2 P24468 1/20 0.37
ABL1 P00519 1/20 0.37
PKM P14618 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
CSNK2A1 P68400 4/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13289285 0.95 MAPK14 (0.44) GSK3BCCNT1CDK2HSD11B1MAPK14
SCHEMBL13120938 0.89 GSK3B (0.61) GSK3BCCNT1CDK2HSD11B1CCND1
SCHEMBL13289292 0.88 GSK3B (0.47) GSK3BCDK2HSD11B1MEN1KMT2A
SCHEMBL14545838 0.88 GSK3B (0.46) GSK3BMEN1KMT2APKMCNR1
SCHEMBL13289294 0.86 GSK3B (0.44) GSK3BCDK2HSD11B1MEN1NPC1
SCHEMBL14545836 0.86 GSK3B (0.43) GSK3BCDK2HSD11B1MEN1KMT2A
SCHEMBL13289289 0.86 CNR1 (0.43) GSK3BCDK2HSD11B1PKMCNR1
SCHEMBL13288949 0.86 GSK3B (0.41) GSK3BCDK2HSD11B1MAPK14MEN1
SCHEMBL13289299 0.85 GSK3B (0.42) GSK3BCDK2HSD11B1MEN1KMT2A
SCHEMBL13289291 0.85 TSHR (0.43) GSK3BCCNT1CDK2HSD11B1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 EP disclosed